<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82426">
  <stage>Registered</stage>
  <submitdate>27/11/2007</submitdate>
  <approvaldate>5/12/2007</approvaldate>
  <actrnumber>ACTRN12607000622404</actrnumber>
  <trial_identification>
    <studytitle>Post-parandial lipid effects of MK-0518  (raltegaravir) vs low-dose ritonavir (100mg daily) in HIV-negative adults</studytitle>
    <scientifictitle>Post-parandial lipid effects of MK-0518 (raltegaravir) vs low-dose ritonavir (100mg daily) in HIV-negative adults</scientifictitle>
    <utrn />
    <trialacronym>RoaR</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Human immunodeficiency virus (HIV)</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Normal development and function of the cardiovascular system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To compare the effects of oral dose ritonavir (RTV) 100mg daily for 28 days to oral dose raltegravir 400mg twice a day for 28 days.</interventions>
    <comparator>ritonavir 100 mg oral per day fro 28 days</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compared the effects of ritonavir (RTV) 100mg daily to those of raltegravir 400mg twice a day on postprandil triglyceride levels in healthy adults over four weeks.</outcome>
      <timepoint>Blood measurements at Visit 1 (Screening -2 to -14 day), Visit 2 (Baseline, 0 hr, 1hr, 2hr, 3hr, 4hr, 5hr, 6hr) and Visit 4 (Week 4, 0hr,1hr, 2hr,3hr,4hr,5hr,6hr)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Comparison of post-prandial lipid effect of oral dose ritonavir 100mg daily and oral dose raltegravir 400mg twice a day. Measure menat of patient lipid laboratory bloods, radial artery tonometry ( measure the function of your arteries and done by placing a probe over the artery in your wrist for about 3o seconds) and Respirometry, (this test measures the speed of your metabolism, as well as  the rate at which fats and sugars are metabolised in the body)</outcome>
      <timepoint>Tonometry and respirometry, will be conducted at Visit 2 and Visit 4 (0hr,1hr,2hr,3hr,4hr,5hr,6hr)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. adults taking a 'normal diet' with a stable weight and no desire to lose or gain weight
body mass index between 20and 30kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. HIV infection
2.use of any medication contra-indictaed with RTG or RTV
3. Fsting triglycerides &lt; 2.0 mmol/l (176 mg/dl)
4. Fasting total cholestrol &lt;6.0 mmol/l (233 mg/dl)
5. use of lipid-lowering therapy
6. Use of anti-hypertensive therapy
7. Diabetes mellitus (fsting glucose &gt;7.0 mmol/l or a prior diagnosis of diabetes)
8. serum hepatic transaminases (AST/ALT) greater than 3 times the upper limit of normal
9. pregnancy or breast feeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/02/2008</anticipatedstartdate>
    <actualstartdate>26/06/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>4/03/2009</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St Vincent's Hospital Sydney</primarysponsorname>
    <primarysponsoraddress>HIV Clinical Trials Unit
IBAC, Xavier Level 4
390 Victroia Street
Darlinghurst NSW 2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Merck Sharpe and Dohme</fundingname>
      <fundingaddress>54-68 ferndell Street
South Granville
NSW 2142</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Garvan Institute of Medical Research</othercollaboratorname>
      <othercollaboratoraddress>384 Victoris Street
Darlinghurst NSW 2010</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A randomized, open-label, 4 week trial. Twenty (22) eligible participants will be randomly assigned to receive 1:1 to raltegravir 400mg bid or ritonavir 100mg mane with food.

Planned sample size:	Twenty two (22) eligible participants.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincents Hospital Sydney</ethicname>
      <ethicaddress>Delacy 15 Building 390 Victoria Street 
Darlinghurst NSW 2010</ethicaddress>
      <ethicapprovaldate />
      <hrec>HREC Reference No: 07/SVH/101HREC Reference No: 07/SVH/101</hrec>
      <ethicsubmitdate>28/11/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor Andrew Carr</name>
      <address>St Vincent's Hospital, Sydney
HIV Clinical Trials Unit, 
IBAC Xavier Level 4
390 Victoria Street
Darlingurst NSW 2010</address>
      <phone>02 8382 3438</phone>
      <fax>02 8382 2090</fax>
      <email>acarr@stvincents.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Richard Norris</name>
      <address>St Vincent's Hospital, Sydney
HIV Clinical Trials Unit, 
IBAC Xavier Level 4
390 Victoria Street
Darlingurst NSW 2010</address>
      <phone>02 8382 2435</phone>
      <fax>02 8382 2090</fax>
      <email>rnorris@stvincents.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Richard Norris</name>
      <address>St Vincent's Hospital, Sydney
HIV Clinical Trials Unit, 
IBAC Xavier Level 4
390 Victoria Street
Darlingurst NSW 2010</address>
      <phone>02 8382 2435</phone>
      <fax>02 8382 2090</fax>
      <email>rnorris@stvincents.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Andrew Carr</name>
      <address>St Vincents Hospital
Xavier, Level 4
390 Victoria St
Darlinghurst, NSW, 2010</address>
      <phone>+61 2 8382 3359</phone>
      <fax />
      <email>acarr@stvincents.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>